{"doi":"10.1111/trf.16152","title":"<scp>SCAR</scp>: The high‐prevalence antigen 013.008 in the <scp>Scianna</scp> blood group system","abstract":"BACKGROUND: The Scianna (SC) blood group system comprises seven antigens. They reside on the erythroblast membrane-associated glycoprotein (ERMAP). The ERMAP and RHCE genes are juxtaposed to each other on chromosome 1. We report a novel SC antigen. STUDY DESIGN AND METHODS: Blood samples came from a patient and his two sisters in Saudi Arabia. To investigate the antibody specificity we used the column agglutination technique and soluble recombinant ERMAP protein. The significance of anti-SCAR was evaluated by the transfusion history and a monocyte monolayer assay. We determined the genomic sequence of ERMAP and RHCE genes. RESULTS: The patient's serum showed an antibody of titer 8 against a high-prevalence antigen. The soluble recombinant ERMAP protein inhibited the antibody. The propositus genotyped homozygous for an ERMAP:c.424C>G variant, for which his sisters were heterozygous. The c.424C>G variant occurred in the SC*01 allele in one haplotype with the RHCE*03 (RHCE*cE) allele. No signs of hemolysis occurred following an incompatible blood transfusion. The monocyte monolayer assay was negative. CONCLUSIONS: We characterized a high-prevalence antigen, with the proposed name \"SCAR,\" which is the eighth antigen of the Scianna blood group system (proposed designation 013.008). Individuals homozygous for ERMAP:p.(Gln142Glu) protein variant can produce anti-SCAR. Although we did not observe any sign of hemolysis at this time, the anti-SCAR prompted a change of the treatment regimen. A review of the known reports indicated that all SC alloantibodies of sufficient titer should be considered capable of causing hemolysis.","journal":"Transfusion","year":2020,"id":111322,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9355,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":528619,"name":"Jasem Albasri","orcid":"0000-0003-2688-6586","position":1,"is_corresponding":false},{"id":529289,"name":"Omar M. Alsuhaibani","orcid":null,"position":2,"is_corresponding":false},{"id":529290,"name":"Hassan Aljasem","orcid":null,"position":3,"is_corresponding":false},{"id":528620,"name":"Marina Bueno","orcid":"0009-0004-6968-9544","position":4,"is_corresponding":false},{"id":529291,"name":"Tania Antonacci","orcid":null,"position":5,"is_corresponding":false},{"id":308480,"name":"Donald R. Branch","orcid":"0000-0002-8974-2451","position":6,"is_corresponding":false},{"id":347480,"name":"Gregory A. Denomme","orcid":"0000-0001-8727-1679","position":7,"is_corresponding":false},{"id":347479,"name":"Willy A. Flegel","orcid":"0000-0002-1631-7198","position":8,"is_corresponding":false},{"id":387829,"name":"Kshitij Srivastava","orcid":"0000-0002-3658-0815","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-18T23:13:05.597252Z","pmid":"33098316","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}